PMEF
SUPN icon

Point72 Middle East FZE’s Supernus Pharmaceuticals SUPN Stock Holding History

Point72 Middle East FZE’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-17,616
Closed -$510K – 1162
2023
Q4 		$510K Buy
+17,616
New +$467K 0.02% 816
2023
Q1 		– Sell
-1,596
Closed -$56.9K – 2185
2022
Q4 		$56.9K Buy
+1,596
New +$55.5K ﹤0.01% 1420

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Point72 Middle East FZE's SUPN Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Supernus Pharmaceuticals (SUPN) in Q1 2024, closing a stake of 17,616 shares — an estimated $510K sold.

Point72 Middle East FZE first reported a position in SUPN in Q4 2022 and held it in 2 quarters. The position peaked at $510K in Q4 2023. 250 funds tracked by Wall St. Rank hold SUPN as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Supernus Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 17,616 Supernus Pharmaceuticals shares in Q1 2024, an estimated $510K.
  • Point72 Middle East FZE first reported a position in Supernus Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Point72 Middle East FZE's Supernus Pharmaceuticals position peaked at $510K in Q4 2023.
  • 250 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.